Cytokinetics, Incorporated (CYTK) Return on equity 2016–2021
Cytokinetics, Incorporated (CYTK) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-88.3%FY2021 · since FY2016: 17.4% → -88.3%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2021 | -88.3% | +24.0 pp |
| FY2020 | -112.3% | — |
| FY2018 | -409.8% | -293.5 pp |
| FY2017 | -116.3% | -133.8 pp |
| FY2016 | 17.4% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice